论文部分内容阅读
目的:探讨采用瑞格列奈治疗2型糖尿病患者的临床疗效及其安全性评价。方法:对本院内科2011年06月至2013年06月收治的122例2型糖尿病患者的临床资料进行回顾性分析,122例患者通过随机数表的方法随机分成两组,常规组61例患者采用临床常规方法进行治疗,研究组61例患者在常规治疗方法的基础上给予瑞格列奈进行治疗,观察和比较两组患者临床治疗的效果以及不良反应发生情况。结果:研究组患者的总有效率为91.80%(56/61),常规组患者的总有效率为80.33%(49/61),两组患者的总有效率差异显著,具有统计学意义(P<0.05);研究组患者临床治疗的不良反应率8.19%(5/61),常规组患者临床治疗的不良反应率8.19%(5/61),两组患者的不良反应率差异不显著,不具有统计学意义(P<0.05)。结论:内科临床上采用瑞格列奈治疗2型糖尿病患者的临床疗效显著,与临床上常规治疗方法相比为出现显著的不良反应,对患者的肝、肾脏功能也未见明显损害,因此该方法值得推广使用。
Objective: To investigate the clinical efficacy and safety evaluation of repaglinide in patients with type 2 diabetes mellitus. Methods: The clinical data of 122 patients with type 2 diabetes mellitus admitted from June 2011 to June 2013 in our hospital were analyzed retrospectively. 122 patients were randomly divided into two groups according to the random number table. In the conventional group, 61 patients The patients in study group were treated with repaglinide on the basis of routine treatment. The clinical effects and adverse reactions in both groups were observed and compared. Results: The total effective rate was 91.80% (56/61) in the study group and 80.33% (49/61) in the conventional group. The total effective rate was significantly different between the two groups (P <0.05). The rate of adverse reactions in the study group was 8.19% (5/61), and that in the routine group was 8.19% (5/61). There was no significant difference in adverse reactions between the two groups Statistically significant (P <0.05). CONCLUSION: Clinical clinical use of repaglinide in patients with type 2 diabetes has significant clinical efficacy, significant adverse reactions compared with the conventional clinical treatment methods, and no significant impairment of the liver and kidney functions of the patients The method is worth promoting.